Biotech and drug stocks, collectively, are down an average of 16% over the past three months. The closely watched XBI index ...

Biotechnology is a rapidly evolving sector with significant advancements anticipated between 2025 and 2035. As innovations in ...

CRISPR Therapeutics AG (CRSP) stock jumped over 9% this week after delivering strong Q4 2024 results ahead of schedule. The ...

CRISPR Therapeutics, the biotech that co-developed the therapy, laid off about 50 employees. “Everyone was dumbfounded,” said a scientist who was let go. It was one early sign that ...

Crispr Therapeutics AG has revenue declines but holds strong financials. Promising Sickle Cell therapy & 2025 data readouts ...

Using cutting-edge genome-editing techniques, including the CRISPR D-BUGS protocol ... with enhanced capabilities for biotechnology applications. "The synthetic yeast genome represents a quantum ...

CRISPR technology has radically transformed genetic research, and at the forefront of this transformation is CRISPR screening ...

Yale researchers have created "Ochre," a genomically recoded organism that enables the production of synthetic proteins with ...

In addition, first-generation CRISPR systems (Cas9 and Cas12a) are too large for efficient in vivo delivery via a single adeno-associated viral (AAV) vector. Now, new preclinical research ...

Using cutting-edge genome-editing techniques, including the CRISPR D-BUGS protocol ... with enhanced capabilities for biotechnology applications. "The synthetic yeast genome represents a quantum ...

I am Debjit, one of the therapeutic analysts here, and joining me from CRISPR Therapeutics is CEO, Samarth Kulkarni. Thank you so much, Sam. Yeah. Happy to do that. I think we’ve been around as ...

Why are CRISPR companies not OK ... that and more on this week’s episode of “The Readout LOUD,” STAT’s biotech podcast. We bring on our colleague Jason Mast to discuss the dramatic ...